Linked Life Data

15264437

Source:http://linkedlifedata.com/resource/pubmed/id/15264437

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2004-7-21
pubmed:abstractText
Genentech, Roche and Chugai are developing pertuzumab, a next-generation trastuzumab-like molecule (an anti-HER/neu monoclonal antibody), for the potential treatment of cancer. Pertuzumab is currently undergoing phase II clinical trials.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1464-8431
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
337-43
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Technology evaluation: pertuzumab, Roche/Genentech/Chugai.
pubmed:affiliation
Guy's Hospital, Department of Medical Oncology, 3rd Floor, New Guy's House, St Thomas Street, London SE1 7EH, UK. James.Spicer@gstt.nhs.uk
pubmed:publicationType
Journal Article, Review